NASDAQ · PASG
Passage Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PASG: Nov 9, 2026
Passage Bio, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.43. The reported EPS for the same quarter last year was $-2.44.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.43 | $-2.43 | $-2.43 | 1 |
| Dec 2026 | $-2.55 | $-2.55 | $-2.55 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · Quiver Quantitative- RTTNews · Jun 26, 10:33 AM EDTWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired(RTTNews) – This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology.
- RTTNews · Jun 25, 4:15 AM EDTPassage Bio And Remix Therapeutics Enter All-Stock Merger Agreement; Stock Down(RTTNews) – Passage Bio, Inc. (PASG),a genetic medicines company and Remix Therapeutics, Inc., a clinical-stage biotechnology company developing small-molecule therapies, announced that they have entered into a definitive merger agreement to merge in an all-stock transaction. The
- Fintel · Mar 31, 6:14 PM EDTOppenheimer Initiates Coverage of Passage Bio (PASG) with Outperform RecommendationFintel reports that on March 31, 2026, Oppenheimer initiated coverage of Passage Bio (NasdaqCM:PASG) with a Outperform recommendation. Analyst Price Forecast Suggests 408.35% Upside
- Fintel · Dec 6, 2:25 PM ESTPassage Bio (PASG) Price Target Increased by 21.85% to 40.39The average one-year price target for Passage Bio (NasdaqCM:PASG) has been revised to $40.39 / share. This is an increase of 21.85% from the prior estimate of $33.15 dated November 14, 2025. The price target is an average of many targets provided by analysts.
- Fintel · Nov 12, 8:23 AM ESTChardan Capital Maintains Passage Bio (PASG) Buy RecommendationFintel reports that on November 12, 2025, Chardan Capital maintained coverage of Passage Bio (NasdaqCM:PASG) with a Buy recommendation. Analyst Price Forecast Suggests 684.87% Upside
- RTTNews · Nov 10, 9:00 PM ESTPASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates(RTTNews) – PASSAGE BIO, INC. (PASG) announced Loss for third quarter that decreased from the same period last year and beat the Street estimates.
- Zacks · Sep 1, 9:55 AM EDTWall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a BetThe mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Aug 15, 9:55 AM EDTWall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to TradeThe mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Quiver Quantitative · Jul 24, 6:15 PM EDTInsider Purchase: 10% owner at $PASG Buys 13,123 SharesCapital Management LP Lynx1, a 10% owner of $PASG, bought 13,123 shares of the company on 07-22-2025 for an estimated $71,337. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately
- Quiver Quantitative · Jul 10, 7:12 AM EDTPassage Bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq CompliancePassage Bio announces a 1-for-20 reverse stock split effective July 14, 2025, to comply with Nasdaq requirements.
- Quiver Quantitative · Jun 23, 7:13 AM EDTPassage Bio Reports Positive Interim Data from Phase 1/2 upliFT-D Trial of PBFT02 for Frontotemporal DementiaPassage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization.
- Zacks · Mar 7, 11:00 AM ESTPassage Bio (PASG) Upgraded to Buy: Here's What You Should KnowPassage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Passage Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.